Loading
Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment.
Kirsten Fischer was principal investigator of CLL14, the German CLL Study Group trial showing twelve months of venetoclax plus obinutuzumab produces deep, MRD-negative remissions and superior progression-free survival compared with chlorambucil-obinutuzumab in unfit patients with untreated CLL, creating the fixed-duration treatment paradigm. She coordinated the CLL8 and CLL10 chemoimmunotherapy trials and leads long-term follow-up of CLL14.
Shares Uniklinik Köln (CIO), BCL-2, CD20, Venetoclax and the tags cll, venetoclax.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares Uniklinik Köln (CIO), CLL14, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, BCL-2.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tags cll, fixed-duration.
Shares CLL14, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, BCL-2, CD20.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing and the tag venetoclax.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tag cll.